Toward as much as they could rer as what happened before that moment or the accumulation of these moments. You know, go back to the beginning. Go back to your childhood. Not as a trite way to excuse what you might have done, not to say that everything depends on the patterns of your life, but his thinking seemed to be if you can understand by learning about yourself enough to know who you were in the moment before the traumatic event, then youll have an easier time understanding how you behaved in the first controlled moment you might be more maybe not forgiveness, but at least theres some understanding built in. So that seemed, you know, is that perfect . No. But for whats available out there, seemed like a pretty good shot. Yeah. I just wanted to make one quick note. Ivem interviewed a couple dozn ptsd survivors, male, female, war veterans, rape survivors. One of the most powerful therapy is the yoga as an alternative therapy because it helps change, the hypervigilance thats associat
Used in a anticochran political video briefly posted online. Won the gop week primary runoff against a rival backed by the departure. Tea party. Journalrows washington we will look at a decisions handed down by the Supreme Court as they wrap up this term. And on the oneyear anniversary of the courts decision on the afense of marriage act, discussion on what has happened nationally since the rulings and whether the issue could return to the courts docket. Also, a detroit reporter joins us to talk about the more the 28 million vehicles that have been recalled this year. We will take your calls and tweets as well. That begins tomorrow at 7 00 a. M. Eastern on cspan. Author Daniel Schulman on the koch brothers. Lawsuitwas a massive between the group mothers and the shareholders, and this terminates in a board room showdown. They were trying to expand the size of the board, and this would have ended up opposing charles is the chairman, and they would have taken a greater role in the directi
CAPE CANAVERAL, Fla., May 09, 2023 Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first. | May 9, 2023